Our round-up of the major patent issues affecting pharma and biotech that emerged on the legal, market and policy fronts last month
The Chinese company also revealed its royalty outflow – $6 billion since it took its first licence in 2001, 80% of which has gone to US companies
Suspension of the probe may not herald a broader deal, but it does underscore the significant legislative concessions China has made on tech transfer and other IP issues
Boost for António Campinos as he ends the first year of his presidency; and good news, too, for USPTO head Andrei Iancu
Move designed to influence debate in Europe and comes on same day as implementers publish their own guidelines.
The Data Business Congress will take place in San Jose, CA, next February with the focus on the capture, protection, management, exploitation and monetisation of one of the pivotal assets of the 21st century
Following successful invalidation petitions lodged by Vivo against the German company, industry sources tell IAM that Oppo, Xiaomi and Meizu also face SEP assertions in specialised IP courts
Recent decisions in Germany, the UK, the Netherlands and France have shed much greater light on where the continent’s top patent litigation venues are heading on FRAND-related disputes
With European Parliament elections next week, and a new Commission in the Autumn, it is vital that policymakers are allowed to focus on what is really important: finding ways to build a true European digital innovation ecosystem
Executives at some of the country's leading domestic mobile manufacturers open up about the reasons they believe an anti-trust investigation of the Swedish company is merited
As this disruptive technology attracts increasing interest, key issuing authorities are developing different ways of handling applications that read on it
A surprise inspection at the Swedish giant’s Beijing office sets the stage for the first big IP probe by China’s new super-regulator
Attorneys say agency’s president has no legal basis for asking the Enlarged Board of Appeal to review the finding that plants produced by biological processes are patentable.
The high invalidation rate for life science patents in China has created a headache for drug companies and a money-making opportunity for enterprising individuals
Judges rule that inventions arrived at by well-established or routine tests can be patented, but the decision will also reassure generics